BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, Ford N, Han Q, Lu Y, Bulterys M, Hutin Y. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:106-19. [PMID: 33197397 DOI: 10.1016/S2468-1253(20)30307-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang SC, Kao JH. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. J Formos Med Assoc 2022:S0929-6646(22)00286-8. [PMID: 35981929 DOI: 10.1016/j.jfma.2022.07.013] [Reference Citation Analysis]
2 Mohareb AM, Larmarange J, Kim AY, Coffie PA, Kouamé MG, Boyd A, Freedberg KA, Hyle EP. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV 2022;9:e585-94. [DOI: 10.1016/s2352-3018(22)00123-0] [Reference Citation Analysis]
3 Sow A, Lemoine M, Toure PS, Diop M, Lo G, De Veiga J, Pape OT, Seck K, Ndow G, Bojang L, Kane A, Oudiane M, Howell J, Nayagam S, Moutchia J, Chemin I, Mendy M, Toure-kane C, Thursz M, Ka M, Shimakawa Y, Mboup S. HBV continuum of care using community- and hospital-based screening interventions in Senegal. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100533] [Reference Citation Analysis]
4 Feng M, Lei L, Xu J, Shi Y, Yang W. Platelet-to-Portal Vein Width Ratio and Platelet-to-Spleen Thickness Ratio Can Be Used to Predict Progressive Liver Fibrosis Among Patients With HBV Infection With HBeAg-Negativity and a Normal ALT Level. Front Med 2022;9:837898. [DOI: 10.3389/fmed.2022.837898] [Reference Citation Analysis]
5 Lim YS, Ahn SH, Shim JJ, Razavi H, Razavi-Shearer D, Sinn DH. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. Aliment Pharmacol Ther 2022. [PMID: 35614532 DOI: 10.1111/apt.17052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.3] [Reference Citation Analysis]
7 Song Y, Shou S, Guo H, Gao Z, Liu N, Yang Y, Wang F, Deng Q, Liu J, Xie Y. Establishment and Characterization of a New Cell Culture System for Hepatitis B Virus Replication and Infection. Virol Sin 2022:S1995-820X(22)00081-5. [PMID: 35568375 DOI: 10.1016/j.virs.2022.05.002] [Reference Citation Analysis]
8 Hsu PK, Su PY, Wu CL. Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B. BMC Gastroenterol 2022;22:228. [PMID: 35538425 DOI: 10.1186/s12876-022-02317-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.2] [Reference Citation Analysis]
10 Matthews PC, Jack K, Wang S, Abbott J, Bryce K, Cheng B, Ghosh I, Story A, Chen J, Munoz C, Bell J, Riddell S, Goldring A, Goddard C, Moraras K, Cohen C, Brown K, Lazarus JV, Elsharkawy AM. A call for advocacy and patient voice to eliminate hepatitis B virus infection. The Lancet Gastroenterology & Hepatology 2022;7:282-5. [DOI: 10.1016/s2468-1253(21)00475-1] [Reference Citation Analysis]
11 Luo Y, Dong Z, Qi S, Li W. Application of Health Education Model Based on Theory of Behavior Change in Nursing Care of Patients with Chronic Hepatitis B. Journal of Nanomaterials 2022;2022:1-7. [DOI: 10.1155/2022/1982554] [Reference Citation Analysis]
12 Ramrakhiani NS, Chen VL, Le M, Yeo YH, Barnett SD, Waljee AK, Zhu J, Nguyen MH. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model. Hepatology 2022;75:430-7. [PMID: 34496066 DOI: 10.1002/hep.32142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Jang H, Lee YB, Moon H, Chung JW, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim YJ, Lee J, Yoon JH. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology 2022. [PMID: 35100447 DOI: 10.1002/hep.32380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.1] [Reference Citation Analysis]
15 Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci 2022;23:1552. [PMID: 35163476 DOI: 10.3390/ijms23031552] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
16 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chen L, Wang X, Yuan Y, Hu R, Chen Q, Zhu L, Gu M, Shen C. Photosensitizers with Aggregation-induced Emission and Their Biomedical Applications. Engineered Regeneration 2022. [DOI: 10.1016/j.engreg.2022.01.005] [Reference Citation Analysis]
18 Le LV, Blach S, Rewari B, Chan P, Fuqiang C, Ishikawa N, Sharma M, Mangadan-Konath N, Razavi H, Low-Beer D, Razavi-Shearer D. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting. Liver Int 2021. [PMID: 34894047 DOI: 10.1111/liv.15131] [Reference Citation Analysis]
19 Vinikoor MJ. TREAT-B: Simple Low-Cost Diagnostic Score for When to Treat Hepatitis B. Clin Infect Dis 2021;73:e1078-9. [PMID: 33277659 DOI: 10.1093/cid/ciaa1820] [Reference Citation Analysis]
20 Sprinzl MF, Feist C, Koch S, Kremer WM, Lackner KJ, Weinmann A, Galle PR. Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. BMC Health Serv Res 2021;21:846. [PMID: 34419018 DOI: 10.1186/s12913-021-06794-6] [Reference Citation Analysis]
21 Yang J, Yue L, Yang Z, Miao Y, Ouyang R, Hu Y. Metal-Based Nanomaterials: Work as Drugs and Carriers against Viral Infections. Nanomaterials (Basel) 2021;11:2129. [PMID: 34443959 DOI: 10.3390/nano11082129] [Reference Citation Analysis]
22 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
23 Rehman ST, Rehman H, Abid S. Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C. World J Hepatol 2021; 13(7): 781-789 [PMID: 34367499 DOI: 10.4254/wjh.v13.i7.781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
24 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Reference Citation Analysis]
25 Ding R, Long J, Yuan M, Zheng X, Shen Y, Jin Y, Yang H, Li H, Chen S, Duan G. CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV. Int J Mol Sci 2021;22:4842. [PMID: 34063629 DOI: 10.3390/ijms22094842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Johannessen A, Mekasha B, Desalegn H, Aberra H, Stene-Johansen K, Berhe N. Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia. Vaccines (Basel) 2021;9:430. [PMID: 33925930 DOI: 10.3390/vaccines9050430] [Reference Citation Analysis]
27 Abdulla M, Ghuloom M, Nass H, Mohammed N, Farid E, ALQamish J. Prevalence of hepatitis B e antigenemia in Bahraini hepatitis B patients: A retrospective, single-center study. JGH Open 2021;5:337-42. [PMID: 33732879 DOI: 10.1002/jgh3.12494] [Reference Citation Analysis]